SCHEDULE 13G - Bicara Therapeutics Inc. (0002023658) (Subject)

10-Q - Bicara Therapeutics Inc. (0002023658) (Filer)

8-K - Bicara Therapeutics Inc. (0002023658) (Filer)

SCHEDULE 13G/A - Bicara Therapeutics Inc. (0002023658) (Subject)

DEFA14A - Bicara Therapeutics Inc. (0002023658) (Filer)

DEF 14A - Bicara Therapeutics Inc. (0002023658) (Filer)

S-8 - Bicara Therapeutics Inc. (0002023658) (Filer)

10-K - Bicara Therapeutics Inc. (0002023658) (Filer)

8-K - Bicara Therapeutics Inc. (0002023658) (Filer)

144 - Bicara Therapeutics Inc. (0002023658) (Subject)

4 - Bicara Therapeutics Inc. (0002023658) (Issuer)

4 - Bicara Therapeutics Inc. (0002023658) (Issuer)

4 - Bicara Therapeutics Inc. (0002023658) (Issuer)

4 - Bicara Therapeutics Inc. (0002023658) (Issuer)

4 - Bicara Therapeutics Inc. (0002023658) (Issuer)

4 - Bicara Therapeutics Inc. (0002023658) (Issuer)

4 - Bicara Therapeutics Inc. (0002023658) (Issuer)

4 - Bicara Therapeutics Inc. (0002023658) (Issuer)

4 - Bicara Therapeutics Inc. (0002023658) (Issuer)

Wells Fargo upgraded Bicara Therapeutics from Underweight to Equal Weight and set a new price target of $8.00

Wells Fargo initiated coverage of Bicara Therapeutics with a rating of Underweight and set a new price target of $8.00

Wedbush initiated coverage of Bicara Therapeutics with a rating of Outperform and set a new price target of $31.00

H.C. Wainwright initiated coverage of Bicara Therapeutics with a rating of Buy and set a new price target of $42.00

Rodman & Renshaw initiated coverage of Bicara Therapeutics with a rating of Buy and set a new price target of $48.00

Cantor Fitzgerald initiated coverage of Bicara Therapeutics with a rating of Overweight

Morgan Stanley initiated coverage of Bicara Therapeutics with a rating of Overweight and set a new price target of $35.00

TD Cowen initiated coverage of Bicara Therapeutics with a rating of Buy

Stifel initiated coverage of Bicara Therapeutics with a rating of Buy and set a new price target of $47.00

BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that members of management will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025 at 3:20 p.m. ET. A live webcast of the presentation will be accessible through the Investor Relations section of Bicara's website under Events and Presentations. A replay of the webcast will be archived and available following the event. About Bicara Therapeutics Bicara Therapeutics is a clinical-stage biopharma

Median DOR of 21.7 months with 80% of responders achieving a deep response (≥80% tumor shrinkage) Depth and durability translating to prolonged OS with median OS of 21.3 months and 2-year OS of 46% in HPV-negative HNSCC Conference call and webcast today at 3:00 p.m. CT / 4:00 p.m. ET BOSTON, June 01, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today presented updated data from the company's Phase 1/1b clinical trial of ficerafusp alfa in combination with pembrolizumab in patients with first line (1L) recurrent/metastatic (R/M) head an

BOSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the publication of an abstract with updated interim data from the company's Phase 1/1b clinical trial of ficerafusp alfa in combination with pembrolizumab in patients with first line (1L) recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) on the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting website. The company will host a conference call on Sunday, June 1, 2025 at 3:00 p.m. CT / 4:00 p.m. ET to present the fulsome dataset

Updated data from ongoing Phase 1/1b trial in 1L R/M HNSCC to be presented at 2025 ASCO Annual Meeting Enrollment ongoing in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC Strong financial position with approximately $462 million in cash and cash equivalents expected to fund operations into the first half of 2029 BOSTON, May 13, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced financial results for the first quarter ended March 31, 2025 and provided a business

BOSTON, April 28, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced multiple presentations related to ficerafusp alfa at the American Association for Cancer Research (AACR) Annual Meeting 2025. Ficerafusp alfa is a first-in-class bifunctional antibody that combines two clinically validated targets: an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β) and is being evaluated across multiple solid tumor types. "We are excited to present s

BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that updated data from the company's ongoing Phase 1/1b clinical trial of ficerafusp alfa in 1L (first line) recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) will be highlighted in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held from May 30-June 3, 2025 in Chicago, IL. Ficerafusp alfa is a first-in-class bifunctional antibody that combines two clinically validated targets:

Dosing commenced in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC Updated data from ongoing Phase 1/1b trial in 1L R/M HNSCC to be presented at 2025 ASCO Annual Meeting Strong financial position with approximately $490 million in cash and cash equivalents expected to fund operations into the first half of 2029 BOSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided

BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that three abstracts relating to the company's lead product candidate, ficerafusp alfa, will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, which will be held from April 25-30, 2025 in Chicago, IL. Ficerafusp alfa is a first-in-class bifunctional antibody that combines two clinically validated targets: an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming

BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that Claire Mazumdar, PhD, MBA, Chief Executive Officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 3:10 p.m. ET. A live webcast of the presentation will be available at Events and Presentations. A replay of the webcast will be archived and available following the event. About Bicara Therapeutics Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional t

BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the first patients have been enrolled in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in combination with pembrolizumab in 1L (first line) recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Ficerafusp alfa is a first-in-class bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor

SC 13G - Bicara Therapeutics Inc. (0002023658) (Subject)

SC 13G - Bicara Therapeutics Inc. (0002023658) (Subject)

SC 13D - Bicara Therapeutics Inc. (0002023658) (Subject)

4 - Bicara Therapeutics Inc. (0002023658) (Issuer)

Median DOR of 21.7 months with 80% of responders achieving a deep response (≥80% tumor shrinkage) Depth and durability translating to prolonged OS with median OS of 21.3 months and 2-year OS of 46% in HPV-negative HNSCC Conference call and webcast today at 3:00 p.m. CT / 4:00 p.m. ET BOSTON, June 01, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today presented updated data from the company's Phase 1/1b clinical trial of ficerafusp alfa in combination with pembrolizumab in patients with first line (1L) recurrent/metastatic (R/M) head an

BOSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the publication of an abstract with updated interim data from the company's Phase 1/1b clinical trial of ficerafusp alfa in combination with pembrolizumab in patients with first line (1L) recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) on the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting website. The company will host a conference call on Sunday, June 1, 2025 at 3:00 p.m. CT / 4:00 p.m. ET to present the fulsome dataset